Drug to get federal review
-
- May
- 31
Progenics Pharmaceuticals Inc. of Eastview and Wyeth Pharmaceuticals announced today that regulators have agreed to review Progenics’ application to market a drug for the treatment of constipation in patients who take certain pain medications. The U.S. Food and Drug Administration has set Jan. 30, 2008, as the date by which it will finish its review of the application for permission to market methylnaltrexone. The FDA’s decision means Progenics is entitled to a $5 million payment from Wyeth. The companies have an agreement to develop the drug.
This entry was posted
on Thursday, May 31st, 2007 at 5:54 pm by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
